H.C. Wainwright reiterates Quantum-Si stock rating at buy on product progress
H.C. Wainwright reiterated a Buy rating and $4.00 price target for Quantum-Si Inc. (QSI), citing product progress. QSI reported Q3 fiscal 2026 results, addressing instrument variability and completing design activities. The company expects first instruments in Q4 fiscal 2026. QSI posted a smaller-than-expected loss of $0.10 per share but missed revenue estimates, reporting $210,000 vs. $280,000 expected. The stock trades at $1.27, with a Fair Value estimate of $1.33.
How this was made
The 30-second read
Why it matters
The earnings beat on loss but miss on revenue prompted H.C. Wainwright to raise its outlook, creating a short‑term bullish catalyst.
Market read
The analyst upgrade provides a clear actionable signal for traders, though the company's cash burn and revenue miss temper the upside.
What to watch
Potential delays in Proteus platform launch and reliance on future orders.
Background
QSI reported Q3 fiscal 2026 results with an adjusted loss of $0.10 per share versus $0.12 expected, but revenue fell 25% to $210k versus $280k consensus.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $4.00 price target on QSI after its Q3 fiscal 2026 earnings showed a smaller loss than expected but a 25% revenue miss.
likely upward pressure as the market prices in the higher target
The new buy rating and $4 target represent a significant upside from the current $1.27 price, providing a clear catalyst for short‑term buying.
Market effects
Highlights ongoing challenges for micro‑cap biotech hardware firms developing next‑gen instruments.
Limited to U.S. small‑cap and biotech investors.
Minimal; primarily affects niche investors in QSI.
Counterpoint
Cash burn rate and revenue shortfall could lead to price weakness despite the upgrade.
Key entities
- companyQuantum-Si Inc.
Micro‑cap developer of advanced instrumentation platforms.
- analyst_firmH.C. Wainwright
Equity research firm that issued the buy rating and price target.
